(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.14%) $79.06
(-0.29%) $2.03
(0.16%) $2 313.40
(0.38%) $26.93
(0.04%) $963.00
(-0.10%) $0.932
(-0.41%) $10.98
(-0.12%) $0.798
(-2.33%) $91.08
Quarter results today
(bmo 2024-05-02)
Expected move: +/- 7.59%
@ $36.11
Išleistas: 14 vas. 2024 @ 20:49
Grąža: 13.17%
Ankstesnis signalas: vas. 13 - 19:40
Ankstesnis signalas:
Grąža: 0.46 %
Live Chart Being Loaded With Signals
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases...
Stats | |
---|---|
Šios dienos apimtis | 550 982 |
Vidutinė apimtis | 940 919 |
Rinkos kapitalizacija | 2.69B |
EPS | $0 ( 2024-02-27 ) |
Kita pelno data | ( $-0.690 ) 2024-06-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -13.99 |
ATR14 | $0.0570 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-13 | Jimenez Freddy A. | Buy | 20 000 | Common Stock |
2024-02-13 | Jimenez Freddy A. | Buy | 4 166 | Common Stock |
2024-02-13 | Jimenez Freddy A. | Sell | 4 166 | Incentive Stock Option (Right to Buy) |
2024-02-13 | Jimenez Freddy A. | Sell | 20 000 | Incentive Stock Option (Right to Buy) |
2024-01-02 | Martin Samuel Bates | Buy | 10 750 | Common Stock |
INSIDER POWER |
---|
75.26 |
Last 97 transactions |
Buy: 2 900 849 | Sell: 507 801 |
Tūris Koreliacija
Celldex Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
NSTS | 0.918 |
BOKF | 0.917 |
FNWD | 0.917 |
GCBC | 0.916 |
NECB | 0.913 |
UMBF | 0.913 |
MSBI | 0.91 |
HMNF | 0.909 |
AHPI | 0.907 |
FSBC | 0.906 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
CHMA | -0.906 |
VTIP | -0.906 |
DSPG | -0.895 |
SUMO | -0.893 |
SOPH | -0.887 |
SMED | -0.882 |
OSMT | -0.878 |
NVCN | -0.876 |
MNTV | -0.876 |
DVCR | -0.872 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Celldex Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Celldex Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $6.88M |
Bruto pelnas: | $3.88M (56.30 %) |
EPS: | $-2.92 |
FY | 2023 |
Pajamos: | $6.88M |
Bruto pelnas: | $3.88M (56.30 %) |
EPS: | $-2.92 |
FY | 2022 |
Pajamos: | $2.36M |
Bruto pelnas: | $957 000 (40.60 %) |
EPS: | $-2.62 |
FY | 2021 |
Pajamos: | $4.65M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.640 |
Financial Reports:
No articles found.
Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.